Citations (30)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Mario Ojeda-Uribe, Valérie Rimelen & Cathérine Marzullo. (2020) Good Profile of Efficacy/Tolerance of Bortezomib or Idelalisib in Waldenström Macroglobulinemia Associated with Acquired Von Willebrand Syndrome. Journal of Blood Medicine 11, pages 67-72.
Read now
Read now
Fotiou Despina, Dimopoulos Meletios Athanasios & Kastritis Efstathios. (2020) Emerging drugs for the treatment of Waldenström macroglobulinemia. Expert Opinion on Emerging Drugs 25:4, pages 433-444.
Read now
Read now
Ramón García-Sanz, Cristina Jiménez, Verónica González De La Calle & María Eugenia Sarasquete. (2018) A safety profile of medications used to treat Waldenström’s macroglobulinemia. Expert Opinion on Drug Safety 17:6, pages 609-621.
Read now
Read now
Jithma P Abeykoon, Uday Yanamandra & Prashant Kapoor. (2017) New developments in the management of Waldenström macroglobulinemia. Cancer Management and Research 9, pages 73-83.
Read now
Read now
Jorge J. Castillo, Zachary R. Hunter, Guang Yang & Steven P. Treon. (2017) Novel approaches to targeting MYD88 in Waldenström macroglobulinemia. Expert Review of Hematology 10:8, pages 739-744.
Read now
Read now
Articles from other publishers (25)
Ramón García-Sanz & Alessandra Tedeschi. (2023) The Management of Relapsed or Refractory Waldenström’s Macroglobulinemia. Hematology/Oncology Clinics of North America 37:4, pages 727-749.
Crossref
Crossref
Karan L. Chohan & Prashant Kapoor. (2023) BTK Inhibitors and Other Targeted Therapies in Waldenström Macroglobulinemia. Hemato 4:2, pages 135-157.
Crossref
Crossref
Ava J. Boutilier, Lina Huang & Sherine F. Elsawa. (2022) Waldenström Macroglobulinemia: Mechanisms of Disease Progression and Current Therapies. International Journal of Molecular Sciences 23:19, pages 11145.
Crossref
Crossref
David Sermer, Shayna Sarosiek, Andrew R. Branagan, Steven P. Treon & Jorge J. Castillo. (2022) SOHO State of the Art Updates and Next Questions: Targeted therapies and emerging novel treatment approaches for Waldenström Macroglobulinemia. Clinical Lymphoma Myeloma and Leukemia 22:8, pages 547-556.
Crossref
Crossref
Sairah Ahmed, Qiuhong Zhao, Walter Hanel, Muzaffar H. Qazilbash, Krina Patel, Ravi Narra, Ankit Kansagra, Madiha Iqbal, Farrukh T. Awan, Beth Christian, Samantha M. Jaglowski, Mohamed A. Kharfan‐Dabaja, Mehdi Hamadani & Narendranath Epperla. (2021) Post‐relapse survival in Waldenstrom macroglobulinemia patients experiencing therapy failure following autologous transplantation. Hematological Oncology 40:1, pages 49-57.
Crossref
Crossref
Jorge J. Castillo. (2021) Novel Agents for Waldenström Macroglobulinemia. Clinical Lymphoma Myeloma and Leukemia 21, pages S34-S35.
Crossref
Crossref
Cécile Tomowiak, Stéphanie PoulainCharles Herbaux, Aurore Perrot, Béatrice MahéPierre MorelThérèse AurranOlivier Tournilhac, Stéphane Leprêtre, Souad AssaadBruno VillemagneOlivier Casasnovas, Delphine NolletDamien Roos-Weil, Sylvie Chevret & Véronique Leblond. (2021) Obinutuzumab and idelalisib in symptomatic patients with relapsed/refractory Waldenström macroglobulinemia. Blood Advances 5:9, pages 2438-2446.
Crossref
Crossref
Christopher N. Grimont, Natalia E. Castillo Almeida & Morie A. Gertz. (2021) Current and Emerging Treatments for Waldenström Macroglobulinemia. Acta Haematologica 144:2, pages 146-157.
Crossref
Crossref
Manisha NautiyalCaroline BauchPaul WalkerPaul B. WatkinsMerrie Mosedale. (2020) Fit-For-Purpose Hepatocyte Models Enable the Identification of Early Events Contributing to Idelalisib-Induced Liver Injury. Applied In Vitro Toxicology 6:4, pages 110-119.
Crossref
Crossref
Jorge J Castillo, Ranjana H Advani, Andrew R Branagan, Christian Buske, Meletios A Dimopoulos, Shirley D'Sa, Marie José Kersten, Veronique Leblond, Monique C Minnema, Roger G Owen, M Lia Palomba, Dipti Talaulikar, Alessandra Tedeschi, Judith Trotman, Marzia Varettoni, Josephine M Vos, Steven P Treon & Efstathios Kastritis. (2020) Consensus treatment recommendations from the tenth International Workshop for Waldenström Macroglobulinaemia. The Lancet Haematology 7:11, pages e827-e837.
Crossref
Crossref
Merrie Mosedale & Paul B. Watkins. (2020) Understanding Idiosyncratic Toxicity: Lessons Learned from Drug-Induced Liver Injury. Journal of Medicinal Chemistry 63:12, pages 6436-6461.
Crossref
Crossref
Saurabh Zanwar, Jithma Prasad Abeykoon & Prashant Kapoor. (2020) Novel Treatment Strategies in the Management of Waldenström Macroglobulinemia. Current Hematologic Malignancy Reports 15:1, pages 31-43.
Crossref
Crossref
Shayna Sarosiek & Jorge J. Castillo. 2020. Novel Therapeutics for Rare Lymphomas. Novel Therapeutics for Rare Lymphomas
15
26
.
Suresh P S, Ravi Kumar Trivedi, Nuggehally R. Srinivas & Ramesh Mullangi. (2019) A review of bioanalytical methods for chronic lymphocytic leukemia drugs and metabolites in biological matrices. Biomedical Chromatography 34:1.
Crossref
Crossref
Merrie Mosedale, Yanwei Cai, John Scott Eaddy, Robert W Corty, Manisha Nautiyal, Paul B Watkins & William Valdar. (2019) Identification of Candidate Risk Factor Genes for Human Idelalisib Toxicity Using a Collaborative Cross Approach. Toxicological Sciences 172:2, pages 265-278.
Crossref
Crossref
Jorge J. Castillo & Steven P. Treon. (2019) What is new in the treatment of Waldenstrom macroglobulinemia?. Leukemia 33:11, pages 2555-2562.
Crossref
Crossref
Wei Liu, Zhen-Tang Jing, Chao-Rong Xue, Shu-Xiang Wu, Wan-Nan Chen, Xin-Jian Lin & Xu Lin. (2019) PI3K/AKT inhibitors aggravate death receptor-mediated hepatocyte apoptosis and liver injury. Toxicology and Applied Pharmacology 381, pages 114729.
Crossref
Crossref
Giuseppe Curigliano & Rashmi R. Shah. (2019) Safety and Tolerability of Phosphatidylinositol-3-Kinase (PI3K) Inhibitors in Oncology. Drug Safety 42:2, pages 247-262.
Crossref
Crossref
Cai-Ming Chen, Wei-Bo Wu, Jian-Feng Chen & Yan Chen. (2019) Characterization of the in vitro metabolites of idelalisib in liver microsomes and interspecies comparison. Journal of Pharmaceutical and Biomedical Analysis 162, pages 249-256.
Crossref
Crossref
M. D’Aveni-Piney, M. Divoux, H. Busby-Venner, M. Muller, J. Broséus & P. Feugier. (2018) Idelalisib in a patient with refractory Waldenström’s macroglobulinemia complicated by anuric renal failure: a case report. Journal of Medical Case Reports 12:1.
Crossref
Crossref
Michael A. Spinner, Gaurav Varma & Ranjana H. Advani. (2018) Novel Approaches in Waldenström Macroglobulinemia. Hematology/Oncology Clinics of North America 32:5, pages 875-890.
Crossref
Crossref
Laurence Simon, Marine Baron & Véronique Leblond. (2018) How we manage patients with Waldenström macroglobulinaemia. British Journal of Haematology 181:6, pages 737-751.
Crossref
Crossref
Morie A. Gertz. (2018) Waldenström macroglobulinemia treatment algorithm 2018. Blood Cancer Journal 8:4.
Crossref
Crossref
Jorge J. Castillo & Steven P. Treon. (2017) Toward personalized treatment in Waldenström macroglobulinemia. Hematology 2017:1, pages 365-370.
Crossref
Crossref
Jonas Paludo, Jithma P. Abeykoon, Shaji Kumar, Amanda Shreders, Sikander Ailawadhi, Morie A. Gertz, Taxiarchis Kourelis, Rebecca L. King, Craig B. Reeder, Nelson Leung, Robert A. Kyle, Francis K. Buadi, Thomas M. Habermann, David Dingli, Thomas E. Witzig, Angela Dispenzieri, Martha Q. Lacy, Ronald S. Go, Yi Lin, Wilson I. Gonsalves, Rahma Warsame, John A. Lust, S. Vincent Rajkumar, Stephen M. Ansell & Prashant Kapoor. (2017) Dexamethasone, rituximab and cyclophosphamide for relapsed and/or refractory and treatment-naïve patients with Waldenstrom macroglobulinemia. British Journal of Haematology 179:1, pages 98-105.
Crossref
Crossref